SESN Sesen Bio Inc.

0.86
+0.02  (+3%)
Previous Close 0.84
Open 0.88
Price To Book 1.33
Market Cap 66898903
Shares 77,456,180
Volume 758,579
Short Ratio
Av. Daily Volume 1,695,662

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initial 12-month data released January 3, 2019 with full due mid-2019.
Vicinium
Non-muscle invasive bladder cancer (NMIBC)

Latest News

  1. Health Stocks Benefitting the Most from Rally
  2. Sesen Bio, Inc. (NASDAQ:SESN): A Fundamentally Attractive Investment
  3. Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer
  4. 4 Healthcare Stocks That Could Test December Highs
  5. Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer
  6. Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer
  7. 3 Health Care Stocks Seeing Heightened Activity After Midterms
  8. Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts
  9. Implied Volatility Surging for Sesen Bio (SESN) Stock Options
  10. Do Institutions Own Shares In Sesen Bio Inc (NASDAQ:SESN)?
  11. Sesen Bio to Present Three-month VISTA Trial Data at Global Congress on Bladder Cancer 2018
  12. Here's Why Momentum Investors Will Love Sesen Bio (SESN)
  13. Sesen Bio (SESN) Continue to Surge Higher?
  14. 3 Cancer Treatment Stocks that Moved Higher in August
  15. Sesen Bio Reports Second Quarter 2018 Financial Results and Pipeline Updates
  16. Sesen Bio Announces Vicinium Granted Fast Track Designation by FDA for Treatment of Non-Muscle Invasive Bladder Cancer
  17. Sesen Bio Announces CEO and Board Transitions as Company Prepares for 12-Month VISTA Trial Data and Regulatory Submission in 2019
  18. Sesen Bio to Present at the Canaccord Genuity 38th Annual Growth Conference
  19. Free Pre-Market Technical Pulse on Sesen Bio and Three More Biotech Stocks
  20. Stock Performance Review on Sesen Bio and Three Other Biotech

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19600784
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19564802
  3. 8-K - Current report 19510938
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19509019
  5. 8-K - Current report 19503602
  6. CT ORDER - Confidential treatment order 181219419
  7. 8-K - Current report 181217402
  8. 8-K - Current report 181184042
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173695
  10. 8-K - Current report 181114159